BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Dalton Pharma Services and The Henry M. Jackson Foundation Announce a Services Agreement for the Advancement of Military Medicine


10/5/2011 12:06:32 PM

Toronto, Ontario (PRWEB) October 05, 2011 -- Dalton Pharma Services, a privately owned Canadian pharmaceutical services provider to leading pharmaceutical companies, today announced the company has entered into a Contract for Service with The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF) to supply and provide sterile fill services for a cGMP grade capsule conjugate vaccine against Campylobacter jejuni developed by the Naval Medical Research Center (NMRC) and Prof. Mario Monteiro (University of Guelph).

Dalton will scale up the conjugation and purification process of a capsule-protein conjugate vaccine intended for use in Phase 1 human clinical trials conducted by NMRC.

“Our expertise and capabilities in conjugation chemistry, sterile API manufacturing and our strength in aseptic filling, solidified the manufacturing agreement," said Peter Pekos, President and CEO of Dalton. “Dalton is committed to supporting the efforts of the Navy and the University of Guelph for novel vaccine research and development.”

About Dalton:

Dalton Chemical Laboratories Inc. o/a Dalton Pharma Services is a Health Canada approved contract pharmaceutical manufacturer that supplies chemistry, analytical and formulation development services to the biotechnology and pharmaceutical industries in the areas of chemistry, medicinal chemistry and fine chemical manufacture. Dalton provides cGMP manufacturing of solid dosage forms and aseptic filling services to its customers at any stage of the regulatory process (Phase I, II, III or commercial). In its state of the art cGMP facilities, Dalton produces active pharmaceutical ingredients at the gram or kilogram scale. Dalton conducts aseptic fills to produce batches of finished drug product in vials or syringes, either aseptically filled or terminally sterilized, under fully validated conditions. In addition, Dalton’s analytical chemistry laboratory offers method development, validation and ICH stability programs to its clients. Further information can be found at http://www.dalton.com.

About HJF:

The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. is a private, not-for-profit organization established in 1983 and authorized by Congress to support medical research and education at the Uniformed Services University of the Health Sciences and throughout the military medical community. Its research support and administrative capabilities allow military medical researchers and clinicians to maintain their scientific focus and to accomplish their goals in a timely and cost-effective manner. For more information, visit http://www.hjf.org.

About Prof. Monteiro:

Mario A. Monteiro is an Associate Professor in the Department of Chemistry at the University of Guelph. His groundbreaking research aims to protect both people and animals from serious disorders. He is developing sugar-based vaccines against gastric pathogens, such Campylobacter jejuni, which causes travellers’ diarrhea; Helicobacter pylori, which causes gastric cancer; and Clostridium difficile, which causes antibiotic-associated diarrhea. For more information, visit http://www.uoguelph.ca/~monteiro/.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES